KEI Research Note 2020:1 Government funding related to the cobas Liat Analyzer PCR testing device. Luis Gil Abinader, April 22, 2020. Introduction Polymerase chain reaction (PCR) testing technique Automatization of the PCR testing technique SARS-Cov-2 emergency use authorizations for PCR… Continue Reading
On September 9, 2019, KEI submitted a second request to the NIH that it investigate an apparent failure to disclose federal funding in patents in adeno-associated viral (AAV) gene therapies assigned to the Trustees of the University of Pennsylvania (UPenn).… Continue Reading
Zolgensma, Novartis’s new $2.1 million gene therapy for children with spinal muscular atrophy (SMA), is a remarkable breakthrough with a steep price tag: the cost per child is $2.125 million. The treatment was developed using research funded by the National… Continue Reading
The Supreme Court today delivered its ruling in the case of Oil States Energy Services, LLC v. Greene’s Energy Group, LLC, holding 7-2 that inter partes review (IPR) is constitutional and does not violate Article III nor the Seventh Amendment.… Continue Reading
Brazil 1990-2000 Comments for the Working Group On Intellectual Property Rights, Third Trade Ministerial and Americas Business Forum, Belo Horizonte, Brazil, May 13-16,1997, 1997-05-16 2005 U.S. DoS Cable: U.S. PHARMA FIRMS THREATENED WITH LICENSING (Brazil), June 3, 2005. U.S. DoS… Continue Reading
On Friday afternoon, 15 December 2017, the 27th session of the WIPO Standing Committee on the Law of Patents (SCP) agreed to a future program of work that included the following topics: 1) Exceptions and Limitations to Patent Rights, 2)… Continue Reading
On Friday, February 24, 2017, KEI hosted a meeting exploring compulsory licensing in the United States.
Title: History, Experiences, and Prospects of Compulsory Licensing on Medical Patents in the United States
Date: Friday February 24, 2017
Location: Kaiser Permanente Center for Total Health
700 Second St. NE (near Union Station)
Washington, DC 20002
The following are selected cables from the US Department of State, obtained under the U.S. FOIA statutes, concerning patents and price negotiations on AIDS drugs. 2004 U.S. DoS Cable: GOB REACHES PRICING AGREEMENTS ON THREE MORE AIDS DRUGS – January… Continue Reading